Search ARM

GenEdit is developing new genetic medicines based on novel non-viral, non-lipid nanoparticles. Compared with other delivery methods, our platform technology has multiple advantages, including payload versatility, payload size, tissue specificity, repeat dosing, lack of pre-existing or acquired immunogenicity, lack of chromosomal integration and cost-effective manufacturing. Our platform consists of our proprietary NanoGalaxy library of polymers that efficiently encapsulate and deliver cargo (RNA, DNA, protein and/or RNP) to target tissues. We use computational analysis and medicinal chemistry for iterative lead optimization to improve specificity and efficiency of in vivo delivery. We have used this platform to identify multiple candidate polymer nanoparticles for efficient and specific delivery of genes and gene editing cargos to a range of tissues and our current therapeutic focus is monogenic CNS diseases.

Contact GenEdit
Visit Website